Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
暂无分享,去创建一个
G. Marit | A. Schmitt | N. Milpied | R. Tabrizi | A. Pigneux | M. Dilhuydy | C. Melot | T. Leguay | X. Lafarge | J. Boiron | K. Bouabdallah | S. Vigouroux | J. Coiffard
[1] H. Einsele,et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.
[2] P. Armand,et al. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] G. Behre,et al. Rituximab reduces the incidence of acute graft-versus-host disease. , 2006, Blood.
[4] J. S. San Miguel,et al. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] F. Mancini,et al. B-Cell Concentration in the Apheretic Product Predicts Acute Graft-Versus-Host Disease and Treatment-Related Mortality of Allogeneic Peripheral Blood Stem Cell Transplantation , 2008, Transplantation.
[6] E. Thiel,et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma , 2007, Bone Marrow Transplantation.
[7] J. Bourhis,et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Ce , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Panse,et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS) , 2006, Bone Marrow Transplantation.
[9] M. Sorror,et al. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] H. Deeg,et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] A. Ghavamzadeh,et al. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation , 2005, Bone Marrow Transplantation.
[12] L. Rybicki,et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation , 2004, Bone Marrow Transplantation.
[13] T. Braun,et al. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes , 2004, Bone Marrow Transplantation.
[14] M. Freund,et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. , 2004, Blood.
[15] N. Schmitz,et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. , 2002, Blood.
[16] K. Sepkowitz,et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. , 2001, Hematology. American Society of Hematology. Education Program.
[17] F. Locatelli,et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. , 2000, Blood.
[18] V. Vitale,et al. Low Transplant Mortality in Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia: A Randomized Study of Low-Dose Cyclosporin Versus Low-Dose Cyclosporin and Low-Dose Methotrexate , 1998 .
[19] A. Nademanee,et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. , 1993, The New England journal of medicine.
[20] H. Deeg,et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter] , 1992 .
[21] J. Kersey,et al. RISK FACTORS FOR ACUTE GRAFT‐VERSUS‐HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION , 1991, Transplantation.
[22] G. Gahrton,et al. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. , 1991, Bone marrow transplantation.
[23] H. Deeg,et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.
[24] K. Sullivan,et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.
[25] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.